• Policy
• MOHW will expand drugs subject to price adjustments
• by Lee, Tak-Sun Dec 5, 2023 05:48am

• Policy
• Tagrisso and Leclaza complete drug pricing negotiations
• by Lee, Tak-Sun Dec 4, 2023 05:13am

• Policy
• Preferential pricing plan will be further discussed by HIPDC
• by Lee, Tak-Sun Dec 4, 2023 05:12am

• Policy
• Novavax’s COVID-19 vaccine receives EUA in KOR
• by Lee, Hye-Kyung Dec 1, 2023 05:35am

• Policy
• Imfinzi's 3-drug combo burden reduced despite nonreimb
• by Lee, Tak-Sun Nov 30, 2023 05:55am

• Policy
• External ref price reevals will be carried out as planned
• by Lee, Tak-Sun Nov 30, 2023 05:55am

• Policy
• BeiGene applies for reimb of its 2nd new drug after Brukinsa
• by Lee, Tak-Sun Nov 29, 2023 05:50am

• Policy
• HIRA starts preparing for RWE-based reimb reevaluations
• by Lee, Tak-Sun Nov 29, 2023 05:50am

• Policy
• DPM Choo ‘will finalize telemedicine plans this year'
• by Kang, Shin-Kook Nov 28, 2023 05:42am

• Policy
• Enspryng and Jemperli will be reimbursed through RSA
• by Lee, Tak-Sun Nov 22, 2023 05:30am